Hypoxia marker labeling in tumor biopsies: Quantification of labeling variation and criteria for biopsy sectioning

Radiotherapy and Oncology

Volumn 44, Issue 2, 1997, Pages 171-176

  Thrall, Donald E ^a   Rosner, Gary L ^b   Azuma, Chieko ^a   McEntee, Margaret C ^a   Raleigh, James A ^c  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Canine tumors; CCI 103F; Hypoxia; Hypoxia markers; Nitroimidazole markers; Sampling error

Indexed keywords

1 (1,1,1,3,3,3 HEXAFLUORO 2 PROPOXY) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; HYPOXIA; LABELING INDEX; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR BIOPSY;

ANIMALS; BIOPSY; CELL HYPOXIA; DOG DISEASES; DOGS; NEOPLASMS; NITROIMIDAZOLES;

EID: 0030788550     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(97)01931-2     Document Type: Article

References (24)

1. Arteel, G.E., Thurman, R.G., Yates, J.M. and Raleigh, J.A. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br. J. Cancer 72: 889-895, 1995.
2. Barranco, S.C., Perry, R.R., Durm, M.E. et al. Intratumor variability in prognostic indicators may be the cause of conflicting estimates of patient survival and response to therapy. Cancer Res. 54: 5351-5356, 1994.
3. Begg, A.C., Hofland, I., Van Glabekke, M., Bartelink, H. and Horiot, J.C. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin. Radiat. Oncol. 2: 22-25, 1992.
4. Brizel, D., Rosner, G.L., Harrelson, J., Prosnitz, L.R. and Dewhirst, M.W. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 30: 635-642, 1995.
5. Chalkley, H.W. Method for the quantitative morphologic analysis of tissue. J. Natl. Cancer Inst. 4: 47-53, 1943.
6. Chapman, J.D., Baer, K. and Lee, J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res. 43: 1523-1528, 1983.
7. Cline, J.M., Rosner, G.L., Raleigh, J.A. and Thrall, D.E. Quantification of CCI-103F labeling heterogeneity in canine solid tumors. Int. J. Radiat. Oncol. Biol. Phys. (in press).
8. Cline, J.M., Thrall, D.E., Rosner, G.L. and Raleigh, J.A. Distribution of the hypoxia marker CCI-103F in canine tumors. Int. J. Radiat. Oncol. Biol. Phys. 28: 921-933, 1994.
9. Cline, J.M., Zeman, E.M., Thrall, D.E. and Raleigh, J.A. Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours. Br. J. Cancer 62: 925-931, 1990.
10. de Jong, J.S., van Diest, P.J. and Baak, J.P.A. Heterogeneity and reproducibility of microvessel counts in breast cancer. Laboratory Investigation 73: 922-926, 1995.
11. Evans, S.M., Jenkins, W.T., Joiner, B., Lord, E.M. and Koch, C.J. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res. 56: 405-411, 1996.
12. 2 saturations. Radiat. Res. 141: 49-56, 1995.
13. Graeber, T.G., Osmanian, C., Jacks, T. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91, 1996.
14. Kennedy, A.S., Raleigh, J.A., Perez, G.M. et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys. (in press).
15. Mueller-Klieser, W., Schlenger, H., Walenta, S. et al. Pathophysiological approaches to identifying tumor hypoxia in patients. Radiother. Oncol. (suppl.) 20: 21-28, 1991.
16. Raleigh, J.A., Dewhirst, M.W. and Thrall, D.E. Measuring tumor hypoxia. Semin. Radiat. Oncol. 6: 37-45, 1996.
17. Raleigh, J.A., Franko, A.J., Breiber, E.O., Lunt, J.A. and Allen, P.S. Covalent binding of fluorinated 2-nitroimidazole to EMT-6 tumours in BALB/C mice. Detection by F-19 nuclear magnetic resonance at 2.35T. Int. J. Radiat. Oncol. Biol. Phys. 12: 1249-1251, 1986.
18. Raleigh, J.A., Miller, G.G., Franko, A.J. et al. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br. J. Cancer 56: 395-400, 1987.
19. Raleigh, J.A., Zeman, E.M., Calkins, D.P., McEntee, M.C. and Thrall, D.E. Distribution of hypoxia and proliferation associated markers in spontaneous canine tumors. Acta Oncol. 34: 345-349, 1995.
20. Thrall, D.E., McEntee, M.C., Cline, J.M. and Raleigh, J.A. ELISA quantification of CCI-103F in canine tumors prior to and during irradiation. Int. J. Radiat. Oncol. Biol. Phys. 28: 649-659, 1994.
21. Urtasun, R.C., Chapman, J.D., Raleigh, J.A., Franko, A.J. and Koch, C.J. Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 12: 1263-1267, 1986.
22. Webster, L., Hodgkiss, R.J. and Wilson, G.D. Simultaneous triple staining for hypoxia, proliferation and DNA content in murine tumors. Cytometry 21: 344-351, 1995.
23. Wordinger, R.J., Miller, G.W. and Nicodemus, D.S. Manual of Immunoperoxidase Techniques. American Society of Clinical Pathologists Press 1987, pp. 52-53.
24. Zeman, E.M., Calkins, D.P., Cline, J.M., Thrall, D.E. and Raleigh, J.A. The relationship between proliferative and oxygenation status in spontaneous canine tumors. Int. J. Radiat. Oncol. Biol. Phys. 27: 891-898, 1993.